Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T12:49:32.121Z Has data issue: false hasContentIssue false
  • English
  • Français

Birth weight, leptin and adiponectin in patients initiating clozapine

Published online by Cambridge University Press:  27 August 2024

L. Ilzarbe ,
M. Garriga ,
C. Oliveira ,
M. Gómez-Ramiro ,
A. Mallorquí ,
V. Ruiz-Cortés ,
Y. Rivas ,
S. Amoretti ,
G. Mezquida  and
D. Ilzarbe
...Show all authors
L. Ilzarbe*
Affiliation:
1Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona 2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
M. Garriga
Affiliation:
1Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona 2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain
C. Oliveira
Affiliation:
4University of Coimbra, Coimbra, Portugal
M. Gómez-Ramiro
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 5Hospital Alvaro Cunqueiro, SERGAS, Translational Neuroscience Research Group, Galicia Sur Health Research Institute (IISGS), Vigo
A. Mallorquí
Affiliation:
6Department of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona
V. Ruiz-Cortés
Affiliation:
6Department of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona
Y. Rivas
Affiliation:
6Department of Psychiatry, Institute of Neuroscience, Hospital Clinic Barcelona, University of Barcelona
S. Amoretti
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 7Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Hospital Clinic, Institute of Neuroscience, University of Barcelona 8Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Psychiatric Genetics Unit, Vall d’Hebron Research Institute (VHIR)
G. Mezquida
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 7Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Hospital Clinic, Institute of Neuroscience, University of Barcelona 9Department of Basic Clinical Practice, Pharmacology Unit, University of Barcelona
D. Ilzarbe
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 10Child and Adolescent Psychiatry and Psychology Department, 2021SGR01319, Institute Clinic of Neurosciences, Hospital Clínic of Barcelona, Barcelona, Spain
E. Vieta
Affiliation:
1Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona 2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain
E. Parellada
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 7Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Hospital Clinic, Institute of Neuroscience, University of Barcelona
I. Baeza
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 7Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Hospital Clinic, Institute of Neuroscience, University of Barcelona 10Child and Adolescent Psychiatry and Psychology Department, 2021SGR01319, Institute Clinic of Neurosciences, Hospital Clínic of Barcelona, Barcelona, Spain
C. García-Rizo
Affiliation:
2Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Barcelona, Spain 7Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Hospital Clinic, Institute of Neuroscience, University of Barcelona
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psychotic patients often require pharmacological treatment, which may prove ineffective, leading to treatment-resistant psychosis necessitating the use of clozapine. However, the emergence of side effects can result in discontinuation, potentially triggering a relapse of psychotic symptoms. One significant side effect is antipsychotic-induced weight gain which, over time, can lead to adverse metabolic events. Recent translational research is evaluating the impact of prenatal factors on the metabolic outcomes of psychotic patients, using a surrogate marker of the intrauterine milieu such as birth weight (BW).

Objectives

We aim to evaluate the changes in leptin, adiponectin, and insulin levels in patients with treatment-resistant psychosis who initiate clozapine treatment due to persistent psychotic symptoms.

Methods

Subjects older than 18 years with a diagnostic of a major mental disorder and initiating clozapine were enrolled in this 18-months longitudinal study. Neurohormones levels, including leptin, adiponeptin, and insulin were measured at baseline, 8 and 18 months during follow-up. Statistical analysis were conducted by using a fixed-effects model.

Results

A total of 23 subjects initiating clozapine were evaluated during the initial mandatory 18-week period. Neurohormones, specifically leptin and adiponectin, were measured at three time points: baseline, 8 weeks, and 18 weeks. The changes in leptin levels were significantly associated with birth BW with sex differences, being inversely correlated only in females. Adiponectin was significantly associated with BW, being inversely correlated in males. Conversely, there was no observed association between insulin levels and BW.

Conclusions

Our findings highlight the significance of prenatal factors in influencing the subsequent evolution of neurohormones in individuals initiating clozapine treatment. This suggests that subjects with lower BW tend to exhibit elevated neurohormone values, emphasizing the role of prenatal events in this context.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S128 - S129
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.